Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.

MLA

Yanishevski, David, et al. “Impact of MYCN Status on Response of High-Risk Neuroblastoma to Neoadjuvant Chemotherapy.” Journal of Pediatric Surgery, vol. 55, no. 1, Jan. 2020, pp. 130–34. EBSCOhost, https://doi.org/10.1016/j.jpedsurg.2019.09.067.

APA

Yanishevski, D., McCarville, M. B., Doubrovin, M., Spiegl, H. R., Zhao, X., Lu, Z., Federico, S. M., Furman, W. L., Murphy, A. J., & Davidoff, A. M. (2020). Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy. Journal of Pediatric Surgery, 55(1), 130–134. https://doi.org/10.1016/j.jpedsurg.2019.09.067

Chicago

Yanishevski, David, M Beth McCarville, Mikhail Doubrovin, Hannah R Spiegl, Xiwen Zhao, Zhaohua Lu, Sara M Federico, Wayne L Furman, Andrew J Murphy, and Andrew M Davidoff. 2020. “Impact of MYCN Status on Response of High-Risk Neuroblastoma to Neoadjuvant Chemotherapy.” Journal of Pediatric Surgery 55 (1): 130–34. doi:10.1016/j.jpedsurg.2019.09.067.